The Course of Hearing Loss in Patients With a Progressive Vestibular Schwannoma

Abstract

AbstractObjectiveThis study evaluates the natural course of hearing loss (HL) prior to treatment in patients with progressive tumors and an indication for active intervention. Evaluating this patient group specifically can put hearing outcomes after vestibular schwannoma therapy into an adequate context.Study DesignRetrospective cohort study.SettingTertiary referral center.MethodsInclusion criteria comprised unilateral vestibular schwannomas prior to active treatment, with ≥2 mm extracanalicular (EC) tumor growth and ≥2 audiograms. We performed a comprehensive assessment of hearing using multiple outcome parameters including (the annual decrease in) pure‐tone averages (PTAs; an average of 0.5, 1, 2, and 3 kHz). Predictors for HL were evaluated (patient age, tumor size/progression, follow‐up duration, baseline hearing).ResultsAt presentation, 86% of patients suffered from sensorineural HL on the affected side (≥20 dB PTA) with a median of 39 dB (interquartile rate [IQR]: 27‐51 dB). The median follow‐up duration was 21 months (IQR: 13‐34 months), after which 58% (187/322) of patients experienced progressive HL (≥10 dB), with a median increase of 6.4 dB/year. At the last follow‐up, the median PTA was 56 dB (IQR: 37‐73). Median speech discrimination scores deteriorated from 90% (IQR: 70%‐100%) to 65% (IQR: 35%‐100%). Tumor progression (maximal EC diameter) was significantly correlated to the progression of sensorineural HL, corrected for follow‐up (F(2,228) = 10.4, p < .001, R2 = 8%).ConclusionThe majority of patients (58%) with radiologically confirmed progressive vestibular schwannomas experience progressive sensorineural HL during observation. Tumor progression rate, EC tumor extension, and longer follow‐up are factors associated with more sensorineural HL.